GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that President &
Chief Executive Officer Rachel King will present at the Canaccord
Genuity Growth Conference in Boston on Wednesday, August 12, 2015 from
5:00 to 5:25 p.m. Eastern Time.
To access the live webcast and subsequent archived recordings for the
presentation at the Canaccord conference, please visit
the GlycoMimetics website at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics entered into an exclusive license
agreement with Pfizer for rivipansel in October 2011. Under the license
agreement, Pfizer is responsible for the clinical development,
regulatory approval and potential commercialization of rivipansel.
A GlycoMimetics wholly owned candidate therapy (GMI-1271) for acute
myeloid leukemia (AML) and other blood disorders is also in clinical
trials. Glycomimetics are molecules that mimic the structure of
carbohydrates involved in important biological processes. Using its
expertise in carbohydrate chemistry and knowledge of carbohydrate
biology, GlycoMimetics is developing a pipeline of glycomimetic drug
candidates that inhibit disease-related functions of carbohydrates, such
as the roles they play in inflammation, cancer and infection. Learn more
at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150810005861/en/
Copyright Business Wire 2015